The Microbiologist-Toxicologist Synergy in European Antimicrobial Stewardship

European hospitals now combat antimicrobial resistance through integrated, rapid collaboration between microbiologists and toxicologists, enabling precision dosing and safer, more effective treatment of multidrug-resistant infections.

Life Sciences Review | Tuesday, February 17, 2026

Within European healthcare, the management of antimicrobial resistance (AMR) has transitioned from an individual prescribing responsibility to a complex, interdisciplinary process. As multidrug-resistant (MDR) organisms become more widespread across the continent, hospital systems are adopting a standardised collaborative model that integrates the diagnostic accuracy of microbiology with the safety considerations of clinical toxicology.

This interdisciplinary partnership is central to contemporary Antimicrobial Stewardship Programs (ASPs), moving the treatment approach from empirical methods to precision medicine that prioritises both pathogen eradication and patient safety. In Europe, this collaboration is characterised as an integrated operational workflow rather than a simple consultation. By coordinating the identification of resistance mechanisms with the careful management of drug toxicity, hospitals are improving outcomes for patients who require last-line therapies.

Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.

Integrated Diagnostic and Toxicokinetic Profiling

Collaboration between disciplines is situated at the intersection of rapid diagnostics and risk stratification. In high-performance European hospital settings, the clinical microbiologist’s role has evolved beyond basic pathogen identification. By employing advanced technologies such as Matrix-Assisted Laser Desorption/Ionisation-Time of Flight (MALDI-TOF) mass spectrometry and rapid genotypic testing, microbiologists now deliver real-time data regarding both organism identity and specific resistance determinants.

This detailed microbiological data provides the immediate foundation for a toxicological strategy. When a resistant pathogen is identified, often necessitating the use of potent yet inherently toxic agents such as polymyxins (colistin) or aminoglycosides, attention shifts to the patient’s toxicological profile. Clinical toxicology and pharmacology specialists use the minimum inhibitory concentration (MIC) values supplied by the microbiologist to model the drug exposure required for bacterial eradication.

Simultaneously, specialists evaluate the patient’s physiological reserve, particularly renal and hepatic function, to estimate the toxicological threshold. This process establishes a therapeutic window based on real-time data: the microbiologist determines the minimum effective dose, while the toxicologist defines the maximum tolerable dose. In contemporary European practice, this collaborative decision-making occurs within hours of admission, enabling precise calculation of initial loading doses for potentially nephrotoxic or ototoxic antibiotics and mitigating the risks of under-dosing, which can promote resistance, or over-dosing, which may result in organ failure.

Precision Dosing and Therapeutic Drug Monitoring (TDM)

The core mechanism of the microbiologist-toxicologist collaboration is the systematic application of TDM. Although TDM was previously limited to a small subset of medications, recent European guidelines have broadened its application to encompass a wide range of anti-infective agents in critical care. This approach addresses the significant variability in drug metabolism observed among critically ill patients, which static dosing guidelines fail to accommodate.

Within this workflow, the microbiologist monitors bacterial responses and supplies updated MIC values if the pathogen demonstrates creeping MICs, defined as a gradual increase in resistance during therapy. Concurrently, the toxicologist or clinical pharmacologist evaluates serum drug concentrations to ensure levels remain within the therapeutic index. This process is especially critical for agents with a narrow therapeutic range, such as vancomycin and amikacin, which are essential in the management of MRSA and resistant Gram-negative infections.

Contemporary clinical strategies employ adaptive dosing software and Bayesian forecasting models that incorporate laboratory data. The toxicologist interprets these pharmacokinetic profiles to recommend dose modifications, such as adjusting dosing frequency or infusion duration, to maximise the period during which drug concentrations exceed the MIC. This iterative process ensures that antibiotic exposure is adequate to eradicate infection while avoiding toxic concentrations. By conceptualising the antibiotic regimen as a variable rather than a static prescription, the team proactively reduces the risk of acute kidney injury, a primary toxicological concern in antimicrobial resistance (AMR) management.

Optimising Combination Therapies for Multidrug-Resistant Pathogens

With the emergence of pan-resistant organisms, defined as bacteria resistant to all standard antibiotics, monotherapy frequently proves inadequate. In response, the prevailing standard in Europe has shifted toward advanced combination regimens that leverage drug synergy, in which two agents demonstrate enhanced efficacy when used together. However, such combinations also increase the risk of additive toxicity, underscoring the importance of collaboration between microbiologists and toxicologists.

Microbiologists play a key role by conducting laboratory fusion tests, such as checkerboard assays or time-kill curves, to identify antibiotic combinations that are bactericidal against specific isolates. For example, they may determine that a particular strain of Klebsiella pneumoniae is susceptible to a combination of ceftazidime-avibactam and aztreonam, despite resistance to each agent individually.

The toxicologist subsequently assesses the safety profile of the proposed antibiotic combination. This evaluation includes analysing the cumulative toxicity burden, such as avoiding the simultaneous use of two nephrotoxic agents when safer alternatives are available. Toxicologists also advise on the timing of drug administration to minimise drug-drug interactions that could result in toxic serum concentrations. This strategic selection process ensures that the aggressive antimicrobial approach necessary to eradicate the bacteria does not inflict physiological harm on the patient.

This collaboration also addresses the limitation of collateral damage. Microbiologists monitor local epidemiological trends to detect Clostridioides difficile outbreaks, which prompts toxicologists and antimicrobial stewards to limit the use of high-risk broad-spectrum antibiotics. This feedback mechanism safeguards the hospital environment by ensuring that interventions for individual patients do not compromise the safety of the broader patient population.

The integration of laboratory and clinical expertise characterises antimicrobial resistance strategies in Europe. The active collaboration between microbiologists and toxicologists demonstrates an advanced approach within healthcare systems, recognising that potent pathogens necessitate equally potent but carefully regulated countermeasures. Combining rapid diagnostic capabilities with toxicokinetic safety management, European hospitals are developing a comprehensive framework for antimicrobial resistance stewardship. This partnership ensures that as bacterial threats evolve, containment strategies remain effective, precise, and prioritise patient safety.

More in News

Pharmaceutical Compliance in a Serialized Supply Chain

Pharmaceutical compliance has moved beyond recordkeeping into the daily movement of product, data and accountability across the supply chain. For manufacturers, wholesale distributors and third-party logistics providers, compliance now depends on whether each package can be identified, verified, traced and reported without forcing teams to reconcile disconnected systems. The pressure is not only regulatory. Counterfeit risk, expired product control, trading partner accuracy and audit readiness all sit inside the same business workflow. A strong compliance platform must bring those demands together without turning compliance into a parallel process that slows commercial activity or leaves leaders dependent on fragmented reports. The most reliable solutions are built around traceability at the transaction level. Serialization cannot be treated as a late-stage attachment to inventory management because the value of a serial number depends on how consistently it travels through purchasing, receiving, sales, returns, financial records and partner exchange. When serialization lives outside the system that manages the business, companies often inherit duplicate entries, timing gaps and inconsistent product data. Those weaknesses become expensive when regulators require proof, customers request verification or leadership needs a clean view of inventory exposure. A better system keeps compliance evidence close to the events that create it, allowing teams to act from the same source of truth rather than comparing data after problems appear. Executives should also look closely at how a platform handles reporting and exception management. Pharma teams need systems that can capture required data, generate reports and support Drug Supply Chain Security Act obligations without relying on manual workarounds. The right solution should reduce dependence on extra staffing for routine tasks, give teams timely visibility into product status and help prevent expired or suspect products from moving forward. Compliance technology should not simply store information. It should make the right information available when a trading partner, regulator or internal leader needs it. That level of discipline becomes especially important for companies operating across multiple states, serving many customers or managing products whose lifecycle data must remain accurate from receipt to distribution. Data protection has become equally central because cloud-based compliance systems hold commercially sensitive information about product movement, customers, orders and financial activity. Encryption, network security, threat detection and compliance controls are no longer supporting features. They are part of the decision. Executives need confidence that the platform protects proprietary data while still enabling authorized users to work across sites, functions and partners. Scalability also matters because pharmaceutical companies rarely remain static. License expansion, new partner relationships, added states, higher transaction volume and broader service lines can quickly expose whether a system was designed for growth or merely configured for a current process. “ For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. “ This is where RxERP stands out as the premier choice for pharmaceutical organizations that need compliance embedded into core business execution rather than added around it. Its platform combines ERP functionality with automated serialization, traceability, reporting, inventory, finance, CRM and business intelligence for manufacturers, distributors and third-party logistics providers. The transcript points to a wholesaler and 3PL that replaced fragmented systems with one integrated platform, improving automation, reporting, data management and DSCSA compliance while achieving measurable financial and revenue gains. For buyers prioritizing traceability, regulatory readiness and unified control, RxERP offers a focused and practical fit. ...Read more

Growing Concerns About Data Continuity in Biopharma Evidence Generation

One of the common concerns within biopharma is not a matter of generating evidence per se. What makes it even harder is the possibility of sustaining a consistent stream of information through several studies or regulations over prolonged periods of time. As such, the issue of data continuity gains more importance as evidence generation software solutions are currently evaluated by potential buyers. Evidentiary initiatives are never limited to the sole scope of their objectives. Information retrieved once can become relevant several times over the life cycle of a particular product. Researchers may need to re-examine certain findings, compare results of treatment between different periods of time or study data acquired within separate research processes. It becomes especially complicated if there are no consistent information sources within an organization. Such considerations begin to impact the choice of evidence generation software. While the tools themselves are hardly ever used to produce any scientific insights directly, their contribution lies in facilitating further evidence processing and management. The problem becomes apparent as evidentiary research programs move past their initial objectives. It is rare for evidence generation initiatives to have a definite deadline or goal. Several years may pass between the start of the research process and its end, which means that there can be many staff changes, reconsiderations of previous assumptions or emergence of new questions. When information proves hard to find or analyze, the whole process can be slowed down significantly. The amount of effort spent tracking documents, verifying the integrity of information and understanding research history may prove to be considerable. At the same time, these aspects might not become a major focus of technology evaluation. Procurement conversations about evidence generation software solutions are shifting in this direction. Buyers' attention moves from operational effectiveness to information sustainability as evidence programs grow more extensive and complex. They are starting to see evidence generation software platforms as tools for sustaining knowledge over time rather than project management resources. This brings a change to the list of priorities for software developers. Features aimed at optimizing research processes are essential but buyers become concerned with data preservation as well. As such, information continuity becomes part of a solution's institutional memory function rather than just another aspect of project management. While data continuity may not be as prominent as some new trends in evidence analytics, it addresses a pressing problem faced by many biopharma teams. Evidence generation projects tend to outlast their budgets, original objectives or even the members of a team conducting research. For biopharma companies investing in such tools, the problem is shifting from acquiring new information to keeping existing data context-sensitive. ...Read more

Choosing Microbial CDMO without Losing Process Control

Commercial biologics programs rarely stall because a sponsor failed to reserve manufacturing capacity. Delays are more likely to appear when fermentation assumptions, purification readiness, assay design and batch documentation fall out of sync. Microbial manufacturing is particularly sensitive at this stage. A process that performs well during development can quickly lose momentum if harvest conditions are not fully understood or impurity clearance has not been aligned with the characteristics of the molecule. For executives evaluating a CDMO, manufacturing capacity is important, but maintaining process continuity is even more critical. The strongest CDMOs do not treat development and manufacturing as separate stages handed from one department to another. Instead, they manage them as a continuous, controlled process. Analytical strategy is developed while the process is still being refined, manufacturing constraints are identified before GMP transfer, sampling routes are planned early and documentation evolves alongside the program instead of being rebuilt for clinical or commercial manufacturing. This goes beyond administrative efficiency. It is an important part of controlling risk. Changes to analytical methods or batch records late in development can trigger comparability work and make regulatory review more challenging. "Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing." A thorough evaluation should also examine how fermentation and purification work together in practice. Separate upstream and downstream suites can offer sponsors greater flexibility, but only if the transition between them is carefully managed. Having real-time harvest data, purification teams ready to receive material, buffers prepared in advance and clear sample routes in place helps avoid the disruption that often occurs between the bioreactor and the first chromatography step. The same level of scrutiny applies to plasmid DNA manufacturing, where supercoiled content, host-cell impurities, endotoxin burden and unwanted isoforms all influence whether the final material is suitable for its intended use. Quality systems should be assessed through evidence, not broad assurances. Every GMP manufacturing program generates extensive documentation, and that record should remain clear and consistent from raw material receipt and media preparation through in-process testing, deviations, investigations and final product release. Buyers should look at whether quality control is integrated closely enough with manufacturing to detect early process signals. They should also consider whether the CDMO has the in-house analytical expertise needed for release testing, stability studies, troubleshooting and comparability work, instead of relying on outside laboratories whenever challenges arise. "For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination." Scale also deserves careful consideration. A larger facility does not automatically make decisions faster, and a smaller specialist may not have enough built-in redundancy. A better question is whether the manufacturing model gives sponsors direct access to scientific expertise while providing the GMP infrastructure needed to support late-stage development and commercial production. That balance is especially important in microbial biologics. Therapeutic proteins, antibody fragments, bacterial vaccines and plasmid DNA each bring different manufacturing demands, so buyers should look beyond broad claims about capacity and examine the depth of process and analytical expertise behind them. Richter BioLogics aligns well with the priorities many sponsors look for when they need microbial expertise backed by GMP manufacturing. Its capabilities span process development, analytical development, microbial GMP manufacturing and plasmid DNA production, including the pART plasmid platform. The company operates independent upstream and downstream processing lines across two multiproduct GMP facilities, with quality control integrated throughout manufacturing campaigns. It supports therapeutic proteins, VHH or Nanobody formats, bacterial vaccines and plasmid DNA. A long GMP manufacturing track record, recent capacity expansion, in-house analytical capabilities and a 2026 FDA inspection with zero observations provide added confidence. For sponsors working to demanding timelines, Richter BioLogics brings together specialized microbial expertise, disciplined documentation, in-house analytical testing and direct project coordination. ...Read more

Inventus welcomes senior figure from Google as a board adviser

Inventus, the only company in the world dedicated to creating purpose-built devices and technology solutions exclusively for clinical trials, has made a key appointment from Google to its advisory board. Mark Bennett, a Vice President at Google, will be working with Inventus in the capacity of Board Adviser. Bennett has more than two decades in senior leadership roles at companies including Microsoft, Sainsbury’s & Tesco. He is currently Google’s Vice President of Knowledge & Information Partnerships for the EMEA region, leading product partnerships for Search, Gemini, Maps, Commerce, Research and Ads . Bennett has spent more than 10 years in Google Partnerships across a range of teams including Knowledge & Information, Android, Google Hardware and Google Play. Bennett’s previous roles at Google include VP for Platforms and Devices Partnerships for the APAC region and Vice President for Google’s Global Android Partnerships. Bennett said he was excited to support Inventus - known for its innovative and industry leading clinical trial solutions - to help map out its next phase of growth. He said: “I’m delighted to be advising the board at Inventus. I’m impressed by the growth and strategy of the company and am looking forward to helping them accelerate that trajectory. I’ve been intrigued by the biomedical sciences sector for some time and seen how AI is an increasingly important factor for the industry. I’ll be advising Inventus on how technology can be harnessed to enhance the efficiency, effectiveness and overall impact of clinical trials, helping bring better treatments to patients faster.” Bennett is the second key appointment from Google at Inventus in recent months. Earlier this year, Jon French, Managing Director of Google’s Android Global Business, was appointed Group Managing Director at Inventus. Commenting on Bennett’s new role, French said: “I could not be more excited to welcome Mark to the Inventus advisory board. I know personally what an incredible leader Mark is. His expertise and perspective will be tremendous assets to our business. “As Inventus enters its next phase of growth, his experience, judgement and strategic vision will help shape our direction and strengthen our ability to achieve our long-term ambitions. At the heart of everything we do at Inventus is a commitment to help bring life-changing treatments to patients faster.” Bennett is the second appointment to the Inventus advisory board – he joins Stacy Hurt, chief patient officer at Parexel, who was welcomed as a Board Adviser in the summer. Parexel is a global clinical development partner. Hurt leads efforts to integrate patient perspectives into drug development and healthcare at their earliest stages. Hurt has more than two decades of leadership experience in the pharmaceutical space. She has worked for GlaxoSmithKline, Transdermal Therapeutics and Colon Cancer Coalition across sales, training and development and has over a decade of experience in patient advocacy. Steve Sanghera, CEO and Co-Founder of Inventus, said: “I am delighted to announce the exceptional appointment of Mark Bennett to the Inventus Board. Mark brings world class technology leadership and knowledge which will be instrumental in guiding our journey as we navigate how AI will shape and influence clinical trials. Mark’s appointment reflects the continuous growth of Inventus within the industry. Together with Stacy, the expertise that we now have at Inventus also demonstrates our commitment to building a business that focuses on technological excellence and the patients which sit at the heart of a clinical trial.” ...Read more

Specials

The Microbiologist-Toxicologist Synergy in European Antimicrobial Stewardship

European hospitals now combat antimicrobial resistance through integrated, rapid collaboration between microbiologists and toxicologists, enabling precision dosing and safer, more effective treatment of multidrug-resistant infections.